Pharma: Establish Quality Control System Comply with Japanese GMP

Meiji Holdings Co., Ltd. Financial Results - For the First Half of FYE March 2018 -

	TOP

	Financial Results - For the First Half of FYE March 2018 -

	Contents

	1. Overview for the First Half

	2. Outlook for the Second Half and Full-year Summary - FYE March 2018 Use of Cash Flows Food: Grow in Sales of Domestic Core Products and International Business, and Reduce Cost Food: Steadily Grow Sales of Probiotics and Yogurt Food: Continue Sales Growth of Chocolate - Health and Premium Food: Bean to Bar - Meiji's strength Food: Change the Packaging for Drinking Milk Food: Business in China - Realize Solid Growth with Profit Increase Food: Establish Integrated R&D System and Create Unique Values Pharma: Steady Sales Growth and Further Low-Cost Operation Pharma: Steady Sales Growth Focusing Mainstay Brand-name Drugs and Generic Drugs in Japan (1) Pharma: Steady Sales Growth Focusing Mainstay Brand-name Drugs and Generic Drugs in Japan (2) Pharma: Started Selling Generic Drugs Manufactured in Medreich on Schedule in Japan Pharma: Establish Quality Control System Comply with Japanese GMP

	Appendix

	Back cover

Pharma: Establish Quality Control System Comply with Japanese GMP

Prev. Page

Next Page

Download the PDF

Quality control/assurance system in Medreich
Quality control/assurance: comply with Japanese regulations

• Manufacturing: trained by Japanese engineers and comply with Meiji Quality Assurance Policies

• Medreich is not the Meiji Seika Pharma's first overseas production plant.
Has vast experience in Indonesia and Thailand to manufacture drugs for Japan

• Manufacturing in Medreich going well

• Tablets from Medreich: inspected and packaged at the Odawara Facility to ensure quality

Pharmaceutical business is in the harsh environment - achieve sustainable growth

• Facing drastic changes in the operating environment

• Secure a stable supply of high-quality, low-cost drugs from Medreich